Insilico Medicine Will Present Phase I ISM6331 Data
The company will share trial results for its oral pan-TEAD inhibitor at the 2026 ESMO Congress in Madrid.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Will AI-designed medicines significantly reduce the time required to bring new treatments to patients?
Insilico Medicine is scheduled to present initial Phase I clinical data for ISM6331, a pan-TEAD inhibitor, at the ESMO Congress 2026 on October 25, 2026. The oral small-molecule drug is currently being evaluated in a trial for patients with advanced solid tumors.
Why it matters
ISM6331 aims to disrupt tumor-promoting signals driven by dysregulation of the Hippo pathway. The drug has received both Orphan Drug Designation for mesothelioma and Fast Track Designation from the FDA to accelerate its development.
The clinical trial evaluates ISM6331 in patients with advanced solid tumors, following its progression from a preclinical candidate nominated in June 2023. The study is cataloged under abstract #997 for the upcoming medical congress.
The players
Insilico Medicine
A biotechnology company based in Cambridge, Massachusetts, that uses artificial intelligence for drug discovery and development.
ESMO Congress
An annual international medical meeting that brings together oncologists and researchers to present advancements in cancer treatment.
The details
Developed using the Chemistry42 generative chemistry platform, ISM6331 functions as a non-covalent inhibitor. The company, which listed on the Hong Kong Stock Exchange in late 2025 under stock code 3696, continues to advance this pipeline candidate.
Timeline
June 2023: ISM6331 was nominated as a preclinical candidate.
June 2024: The FDA granted the drug Orphan Drug Designation.
January 2025: The Phase I clinical trial was initiated.
December 30, 2025: Insilico Medicine listed on the Hong Kong Stock Exchange.
July 2026: The FDA granted the drug Fast Track Designation.
The Big Picture
The use of the Chemistry42 generative chemistry platform represents a shift from traditional drug discovery to AI-driven molecular design. This story highlights the practical application and clinical advancement of a drug molecule designed through this specific AI platform.
The Fast Track and Orphan Drug designations signal that this drug is intended to provide new treatment options for patients with advanced solid tumors and mesothelioma. These regulatory statuses may accelerate the timeline for potential future availability of the therapy.
The takeaway
ISM6331 represents a significant step in utilizing generative AI to target the Hippo pathway in oncology. Ongoing clinical trials will determine if this specific mechanism provides improved outcomes for patients with advanced solid tumors.
What happens next
Initial Phase I data for ISM6331 will be presented at the ESMO Congress in Madrid on October 25, 2026.
Further reading
Learn more about the latest research in the field of Cancer.
More information
Review the full Phase I clinical trial details regarding this study.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Will AI-designed medicines significantly reduce the time required to bring new treatments to patients?
